Navigation Links
Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
Date:9/2/2008

nts studied in ATHENA were either 75 years of age or older (with or without cardiovascular risk factor) or above 70 years of age with at least one additional cardiovascular risk factor (hypertension, diabetes, previous cerebrovascular event, left atrium size greater than 50 mm or left ventricular ejection fraction lower than 40%). Patients were randomized to receive Multaq(R) 400 mg BID or placebo, with a maximum follow-up of 30 months.

The ATHENA study objectives were to show a potential benefit of Multaq(R) on the primary composite endpoint of all-cause mortality combined with cardiovascular hospitalization as compared to placebo. The pre-specified secondary endpoints were death from any cause, cardiovascular death and hospitalisation for cardiovascular reasons. The pre-specified safety endpoint was the incidence of treatment emergent adverse events (between first study drug intake and last study drug intake plus 10 days) including: all adverse events, serious adverse events, adverse events leading to study drug discontinuation.

The ATHENA stroke post-hoc analysis on a non-pre-specified secondary endpoint was conducted in order to confirm the consistent benefit of Multaq(R) in atrial fibrillation or atrial flutter patients in reducing major cardiovascular complications like stroke, which is a leading cause of cardiovascular hospitalizations or death in this patient population.

About Multaq(R) (dronedarone)

Multaq(R) is an investigational treatment and the only anti-arrhythmic drug (AAD) to have shown a significant reduction in morbidity and mortality in atrial fibrillation /atrial flutter patients with a favourable safety profile as evidenced by a low incidence of pro-arrhythmia (including torsades de pointes) and extra-cardiac organ toxicity.

Multaq(R), discovered and developed by sanofi-aventis, has been studied in a clinical development program including more than 7,000 patients. Multaq(R) is one of the major therapeutic innov
'/>"/>

SOURCE Sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
2. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
3. Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies
4. Published Guidelines Further Support Use of Bioimpedance Measurement Technology for Early Assessment of Lymphedema
5. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
6. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
7. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
8. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
9. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
10. Arpida Provides Further Comments on the Pivotal Phase III Trials
11. Molecular Science Could Further Improve Leukemia Survival, Say St. Jude Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015 Young ... supplies and equipment, today announced the acquisition of ... Products Laboratories, Inc. ("MPL PDCMD"). MPL PDCMD manufactures ... in preventive and restorative dental procedures. ... of our business in attractive, high-growth segments," said ...
(Date:8/4/2015)... , Aug. 4, 2015  Rigel Pharmaceuticals, Inc. (Nasdaq: ... quarter and six months ended June 30, 2015. ... ITP are progressing and we continue to expect results ... , president and chief executive officer of Rigel. "We ... clinical programs, including evaluating fostamatinib for new treatment indications, ...
(Date:8/4/2015)... , Aug. 4, 2015  Dr. Keesha ... the potential FDA approval of flibanserin, or what ... and the treatment of decreased female sexual desire ... many root causes and addressing libido as a ... ...
Breaking Medicine Technology:Young Innovations Announces Acquisition of Medical Products Laboratories' Professional Dental Contract Manufacturing Division 2Rigel Announces Second Quarter 2015 Financial Results 2Rigel Announces Second Quarter 2015 Financial Results 3Rigel Announces Second Quarter 2015 Financial Results 4Rigel Announces Second Quarter 2015 Financial Results 5Rigel Announces Second Quarter 2015 Financial Results 6Potential FDA Approval of "Pink Viagra" Sends Wrong Message 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 3Potential FDA Approval of "Pink Viagra" Sends Wrong Message 4Potential FDA Approval of "Pink Viagra" Sends Wrong Message 5
... /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP ) ... biotechnology research and development outsourcing company, today announced that ... growing capacity needs of one of its largest customers, ... it has signed a multi-year extension of its contract ...
... 10, 2012 Reportlinker.com announces that ... available in its catalogue: ... Market Outlook in BRICS (Brazil, Russia, ... http://www.reportlinker.com/p0750215/Magnetic-Resonance-Imaging-MRI-Systems-Market-Outlook-in-BRICS-Brazil-Russia-India-China-South-Africa-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging ...
Cached Medicine Technology:ShangPharma Announces Opening of New Facility to Support Lilly's Pipeline 2ShangPharma Announces Opening of New Facility to Support Lilly's Pipeline 3Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 2Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 3Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 4Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 5Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 6Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 7Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 8Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 9Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 10Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 11Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 12Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 13Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 14Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 15Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 16Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017 17
(Date:8/4/2015)... ... August 05, 2015 , ... ... as a 2015-2016 inductee into its VIP Woman of the Year Circle. She ... nation’s leading networking organization exclusively for professional women, boasting more than 700,000 members ...
(Date:8/4/2015)... ... August 05, 2015 , ... The Journal of ... Obesity ”. , As corresponding author Professor Akiko Okifuji says “Both obesity and chronic ... it is not to say that one causes the other. Rather, there appear to ...
(Date:8/4/2015)... ... August 04, 2015 , ... assistPoint Partners, ... innovation to consolidate oncology patient assistance programs. Through a secure web portal, assistPoint ... assistPoint is an enterprise level, cloud-based application and workflow solution. This provides cancer ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... organization which provides vascular, electrocardiogram (EKG), echocardiogram, and NCV testing, announced their ... been successfully identifying previously undiagnosed cardiovascular abnormalities one program at a time. ...
(Date:8/4/2015)... , ... August 04, 2015 , ... Bayco Products, Inc. ... enough to fit, for example, on hard hats that have a flip-up face shield. ... allows users to work without having to remove their headlamp when raising or ...
Breaking Medicine News(10 mins):Health News:NAPW Inducts Deborah Stevens, Executive Assistant to Chairman and CEO at Mirion Technologies, Inc., Into its VIP Woman of the Year Circle 2Health News:The Association between Chronic Pain and Obesity published by Dove Medical Press 2Health News:assistPoint.com Web Site Launched 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3
... June 19 The telephone number for the suicide prevention ... being carried on more than 21,000 city buses in 124 ... 1, 2009. , , The advertisements carry a message ... are undergoing an emotional crisis. , , "We ...
... Move comes after FDA reports 66 cases of E. ... (HealthDay News) -- U.S. health officials are warning consumers not ... because of the risk of E. coli contamination. ... Nestlé USA said Friday that it was voluntarily recalling its ...
... autistic child filed a motion in federal court today to confirm ... Michigan. The family alleged in the suit that the insurer ... disorder (ASD), on the baseless ground that the care was "experimental." ... reached at a court-ordered conference on Wednesday, June 17, 2009, Blue ...
... comes after FDA reports 66 cases of E. coli ... News) -- U.S. health officials are warning consumers not to ... of the risk of E. coli contamination. , ... USA said Friday that it was voluntarily recalling its Toll ...
... High Clinical Cure Rates in Adult Patients Hospitalized for Moderate ... 2009 Forest Laboratories, Inc. (NYSE: FRX ) ... studies of ceftaroline for the treatment of community-acquired bacterial pneumonia ... trials (FOCUS I and II) demonstrate that ceftaroline met the ...
... former CEO of FedEx Kinko,s, has been re-elected Chairman of the ... today. , , "Ken May is a strong and effective ... Jennifer L. Howse, President of the March of Dimes. "We look ... of giving every baby a healthy start in life." , ...
Cached Medicine News:Health News:Nestlé Recalls Cookie Dough Products 2Health News:Blue Cross Blue Shield of Michigan Forced to Pay for Autism Care In Landmark Case 2Health News:Blue Cross Blue Shield of Michigan Forced to Pay for Autism Care In Landmark Case 3Health News:Nestlé Recalls Raw Cookie Dough Products 2Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 2Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 3Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 4Health News:Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization 5
Inquire...
Inquire...
... Series II Power Supplies. The EPS-2000-II, ... EPS-6000-II. These high-voltage power supplies offer ... power operating modes, with automatic crossover ... current/300 watts maximum power (except for ...
... The PowerPac HV high-voltage ... V, supports an increased output ... and 400 W. Built-in infrared ... transfer. Power cord and instructions ...
Medicine Products: